GTC Biotherapeutics received $7 million in debt financing from strategic partner LFB Biotechnologies SAS. The financing was contingent on a restructuring of GTC’s operations; the company will eliminate approximately 30 full-time positions at its headquarters and an additional 20 positions at its farm facility. In addition, chief executive officer, president and chairman Geoffrey Cox and several other members of the current senior management team will exit GTC. Board member William Heiden has bee...